Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

907 - EVIDENS: An observational study of Nivolumab-treated patients in Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-world Setting: initial results on 1394 Patients (NCT03382496, BMS sponsored)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Immunotherapy

Tumour Site

Presenters

Adrien Dixmier

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

A. Dixmier1, D. Debieuvre2, C. Raspaud3, J.B. Auliac4, N. Benoit5, P. Bombaron6, B. Asselain7, A. Dumont8, P. Lamoureux9, N. Goyard10, D. Moro-Sibilot11, M. Perol12, F. Barlesi13, C. Audigier Valette14

Author affiliations

  • 1 Pneumologie Et Oncologie Thoracique, C.H.R. Orleans - La Source, 45100 - Orleans/FR
  • 2 Service De Pneumologie, Hôpital Emile Muller, GHRMSA, 68100 - Mulhouse/FR
  • 3 Pneumologie, Clinique Pasteur, 31076 - Toulouse/FR
  • 4 Pneumologie, CH François Quesnay, 78201 - Mantes La Jolie/FR
  • 5 Pneumologie, Clinique de l'Europe, 80000 - Amiens/FR
  • 6 Pneumologie-cancérologie, Hôpital privé Jean Mermoz, 69008 - Lyon/FR
  • 7 Biostatistics, Institut Curie, 75005 - Paris/FR
  • 8 Immuno-oncology Lung Medical Affairs, Bristol-Myers Squibb, 92500 - Rueil-Malmaison/FR
  • 9 Excellence Opérationnelle Médicale, Bristol-Myers Squibb, Vandoeuvre les Nancy/FR
  • 10 Global Clinical Trial Strategy And Operations, Bristol-Myers Squibb, 92500 - Rueil-Malmaison/FR
  • 11 Pneumologie, Centre Hospitalier Universitaire de Grenoble Alpes, 38700 - Grenoble/FR
  • 12 Cancérologie Médicale, Centre Léon Bérard, 69008 - Lyon/FR
  • 13 Service D'oncologie Multidisciplinaire Et Innovations Thérapeutiques, Aix-Marseille Université; Assistance Publique Hôpitaux de Marseille, 13015 - Marseille/FR
  • 14 Pneumology, Hospital Sainte Musse, 83100 - Toulon/FR
More

Resources

Abstract 907

Background

Nivolumab demonstrated efficacy and safety in patients previously treated for advanced NSCLC in two phase 3 trials: CheckMate 017 and 057. Real‐world data in a large unselected population are needed to support these results. EVIDENS aims to describe clinical characteristics of NSCLC patients treated with nivolumab in real-life in France and to assess its efficacy and safety.

Methods

EVIDENS is an observational, multicenter, longitudinal cohort study of adult NSCLC patients treated with nivolumab in a representative sample of general hospitals, university hospitals and private clinics in France. From Dec 2016 to Nov 2017, 186 sites participated in the study. We report here a pre-planned analysis including patients with confirmed NSCLC treated with at least one dose of nivolumab with a minimum of 6 months of follow-up. Kaplan-Meier estimates were derived for PFS and medians with their 95% confidence intervals.

Results

At data cut off April 20, 2018, 1394 NSCLC patients received nivolumab, including 434 (31.1%) with Squamous (Sq)-NSCLC and 960 (68.9%) with non-Sq-NSCLC. Baseline patient characteristics were representative of a standard advanced NSCLC population: median age 66.0 years (range 35-91), 69.2% men, 89.6% current and former smokers, 83.2% PS 0-1. 279 (20.0%) patients had brain metastases and 41 (2.9%) patients had active autoimmune disease. PD-L1 was tested in 187 patients and expressed (≥1%) in 121 (64.7%) patients. Of the 828 non-Sq NSCLC patients tested, 46 (5,5%) had EGFR mutations. Nivolumab was administered in 2nd and ≥3rd line for 74.4% and 25.3% of patients respectively. Median PFS since inclusion was 3 months (95%CI 2.96-3.61). Adverse events occurred in 885 (63.5%) patients, including 145 (10.4%) grade 3/4 events.

Conclusions

These preliminary results of EVIDENS confirm both the activity and safety profile of nivolumab in the ≥2nd line setting in usual clinical practice, including patient populations under-represented in pivotal clinical trials. Outcomes over a longer follow-up period (minimum potential 12 months) and OS data will be presented during the congress.

Clinical trial identification

NCT03382496.

Legal entity responsible for the study

Bristol-Myers Squibb France.

Funding

Bristol-Myers Squibb France.

Editorial Acknowledgement

Disclosure

A. Dixmier: Bristol Myers Squibb, Roche. D. Debieuvre: Consulting: Roche; Honoraria : AstraZeneca, Chugai, Lilly, Roche, Novartis, Pfizer, MSD, BMS; Funding for research: Roche, AstraZeneca, Lilly, BMS, Boehringer Ingelheim, Chiesi, Chugai, Janssen, Pfizer, MSD, Novartis, GSK, Sandoz; Expertise (board): Roche, Boehringer Ingelheim, Pfizer, MSD, BMS, Novartis; Honoraria (congress invitation): Roche, Boehringer Ingelheim, Novartis, Pierre Fabre, Pfizer, Mundipharma, BMS. C. Raspaud: Novartis, Boehringer-Ingelheim, GSK, Chiesi, BMS, MSD, AstraZeneca, SOS O2, Agir Adom, Lilly. J.B. Auliac: Advisory board: BMS, Roche, AstraZeneca, Boehringer; Grant: BMS, Roche, AstraZeneca, Boehringer, MSD, Amgen, Pfizer. N. Benoit: BMS, AstraZeneca. P. Bombaron: BMS, Novartis, Boehringer Ingelheim, Roche, Amgen. B. Asselain: Scientific Committee, Speaker: BMS. A. Dumont, P. Lamoureux, N. Goyard: Employee: BMS. D. Moro-Sibilot: Advisory board: Roche, Pfizer, AstraZeneca, BMS, MSD, Lilly, Boehringer, Abbvie, Takeda Corporate; Sponsored research: Boehringer, Abbvie. M. Perol: Honoraria for Advisory Board: BMS. C. Audigier Valette: Principal investigator for clinical trials: AstraZeneca, Boehringer Ingelheim, BMS, Novartis, Roche; Consulting/Advisory board: AstraZeneca, Boehringer Ingelheim, BMS, Lilly, Novartis, MSD, Pfizer, Roche; Speaker: AstraZeneca, Boehringer Ingelheim, BMS, Lilly, Novartis, Pfizer, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.